Cargando…
Nano‐optogenetic immunotherapy
Chimeric antigen receptor (CAR) T cell‐based immunotherapy has been increasingly used in the clinic for cancer intervention over the past 5 years. CAR T‐cell therapy takes advantage of genetically‐modified T cells to express synthetic CAR molecules on the cell surface. To date, up to six CAR T cell...
Autores principales: | Huang, Kai, Liu, Xiaoxuan, Han, Gang, Zhou, Yubin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471049/ https://www.ncbi.nlm.nih.gov/pubmed/36101937 http://dx.doi.org/10.1002/ctm2.1020 |
Ejemplares similares
-
Nano-Optogenetic Engineering of CAR T-cells for Precision Immunotherapy with Enhanced Safety
por: Nguyen, Nhung Thi, et al.
Publicado: (2021) -
Red‐shifted optogenetics comes to the spotlight
por: Wang, Tianlu, et al.
Publicado: (2022) -
Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
por: Dou, Yaling, et al.
Publicado: (2023) -
Is magnetogenetics the new optogenetics?
por: Nimpf, Simon, et al.
Publicado: (2017) -
Optogenetic Control of Voltage‐Gated Calcium Channels
por: Ma, Guolin, et al.
Publicado: (2018)